Biomea Fusion (BMEA) Stock Analysis

What Biomea Fusion does

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Key metrics

ETFs linked to BMEA

Broad-market and Healthcare sector ETFs an investor holding Biomea Fusion is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BMEA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Biomea Fusion?

Biomea Fusion trades under the ticker BMEA on NASDAQ.

Which exchange is BMEA listed on?

BMEA is listed on NASDAQ.

What sector does Biomea Fusion operate in?

Biomea Fusion is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze BMEA in a portfolio?

PortView shows BMEA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.